Oct 26, 2026 11:31AM
Oct 26, 2026 11:30AM
Sep 10, 2026 08:30AM
Sep 8, 2026 07:19AM
Aug 6, 2026 06:45AM
Aug 6, 2026 06:45AM
Apr 30, 2026 06:30AM Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
Apr 21, 2026 08:37AM
Apr 21, 2026 06:45AM
Apr 21, 2026 06:45AM
Apr 20, 2026 06:48AM
Apr 20, 2026 06:48AM
Apr 13, 2026 07:01AM
Apr 13, 2026 07:00AM Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Bas
Mar 2, 2026 06:26AM
Feb 28, 2026 10:05AM
Feb 28, 2026 10:05AM
Feb 28, 2026 10:00AM
Feb 25, 2026 12:37PM
Feb 25, 2026 12:37PM
Feb 3, 2026 06:30AM Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Nov 19, 2025 06:45AM
Nov 19, 2025 06:45AM
Oct 23, 2025 06:00AM
Oct 23, 2025 06:00AM
Oct 18, 2025 10:35AM
Oct 15, 2025 06:45AM
Oct 15, 2025 06:45AM Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infecti
Sep 19, 2025 06:45AM
Sep 19, 2025 06:45AM
Jul 29, 2025 06:30AM
Jul 10, 2025 06:45AM
Jul 10, 2025 06:45AM
Jul 2, 2025 06:45AM
Jul 2, 2025 06:45AM FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
Jun 13, 2025 11:43AM
Apr 27, 2025 12:00PM
Apr 24, 2025 06:30AM
Mar 27, 2025 11:01AM
Mar 27, 2025 11:01AM
Feb 25, 2025 06:45AM
Feb 25, 2025 06:45AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinom
Feb 4, 2025 06:30AM
Jan 27, 2025 06:45AM
Dec 17, 2024 06:46AM
Dec 17, 2024 06:45AM
Dec 11, 2024 09:44AM
Jul 30, 2024 06:30AM
May 29, 2024 07:17AM Merck (MRK): FDA Grants Priority Review to Application for KEYTRUDA Plus Chemo as First-Line Treatment of Patients With Malignant Mesothelioma
May 29, 2024 07:15AM

15,970 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All